NCT06591858

Brief Summary

To evaluate the effect of subclinical and overt Hyperthyroidism in renal function

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2024

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

September 5, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

September 19, 2024

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

September 19, 2024

Status Verified

September 1, 2024

Enrollment Period

1.5 years

First QC Date

September 5, 2024

Last Update Submit

September 9, 2024

Conditions

Hyperthyroidism

Outcome Measures

Primary Outcomes (1)

  • Evaluation of renal function in patients with subclinical and overt Hyperthyroidism.

    baseline

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with overt Hyperthyroidism ( clinically manifested and laboratory by low TSH, high fT3 \& fT4) And subclinical hyperthyroidism ( low TSH \<0.4.MI/IU without clinical symptoms of hyperthyroidism

You may qualify if:

  • Patients aged (18\_80 years) diagnosed subclinical and overt Hyperthyroidism with overt Hyperthyroidism

You may not qualify if:

  • Patients with D.M
  • Patients with Hypertension
  • Patients with CKD or ESRD
  • IHD
  • Pateints receiving medication known to affect renal function as contrast agent, non-steroidal anti-inflammatory drugs and ACEIs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hyperthyroidism

Condition Hierarchy (Ancestors)

Thyroid DiseasesEndocrine System Diseases

Study Officials

  • Ahmed K Abdelghany

    Assiut University

    PRINCIPAL INVESTIGATOR

  • Hanaa M Riad

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Ahmed K Abdelghaney

CONTACT

201093375923ahmedkhaled0057@gmail.com

Hanaa M Riad

CONTACT

+201094608083hanaaried@gmail.com

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident Doctor

Study Record Dates

First Submitted

September 5, 2024

First Posted

September 19, 2024

Study Start

September 1, 2024

Primary Completion

March 1, 2026

Study Completion

May 1, 2026

Last Updated

September 19, 2024

Record last verified: 2024-09